Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

Pittet, Valérie; Michetti, Pierre; Mueller, Christoph; Braegger, Christian; Känel, Roland von; Schoepfer, Alain; Macpherson, Andrew J.; Rogler, Gerhard; Anderegg, Claudia; Bauerfeind, Peter; Beglinger, Christoph; Begré, Stefan; Belli, Dominique Charles; Bengoa, J M; Biedermann, Luc; Bigler, B.; Binek, Janek; Blattmann, Mirjam; Boehm, Stephan; Borovicka, Jan; Brunner, Nora; Bühr, Patrick; Burnand, Bernard; Burri, Emanuel; Buyse, Sophie; Cremer, Matthias; Criblez, Dominique; Saussure, Philippe de; Degen, Lukas; Delarive, Joakim; Doerig, Christopher; Dora, Barbara; Dorta, Gian; Egger, Mara; Ehmann, Tobias; El-Wafa, Ali; Engelmann, Matthias; Ezri, Jessica; Felley, Christian; Fliegner, Markus; Fournier, Nicolas; Fraga, Montserrat; Frei, Pascal; Fried, Michael; Froehlich, Florian; Funk, Christian; Furlano, Raoul I.; Gallot-Lavallée, Suzanne; Geyer, Martin; Girardin, Marc; Golay, Delphine; Grandinetti, Tanja; Gysi, Beat; Haack, Horst; Haarer, Johannes; Helbling, Beat; Hengstler, Peter; Herzog, Denise; Hess, Cyrill; Heyland, Klaas; Hinterleitner, Thomas; Hiroz, Philippe; Hirschi, Claudia; Hrúz, Petr; Iwata, Rika; Jost, Res; Juillerat, Pascal; Keller, Céline; Knellwolf, Christina; Knoblauch, Christoph; Köhler, Henrik; Koller, Rebekka; Krieger-Grübel, Claudia; Kullak‐Ublick, Gerd A.; Künzler, Patrizia; Landolt, Markus A.; Lange, Rupprecht; Lehmann, Frank Serge; Maerten, Philippe; Maillard, Michel H.; Manser, Christine N.; Manz, Markus G.; Marbet, Urs A.; Marx, George; Matter, Christoph; Meier, Rémy; Mendanova, Martina; Misselwitz, Benjamin; Morell, Bernhard; Mosler, Patrick; Mottet, Christian; Müller, Christoph; Müller, Pascal; Müllhaupt, Beat; Münger-Beyeler, Claudia; Musso, Leilla; Nagy, Andreas; Neagu, Michaela; Nichita, Cristina; Niess, Jan Hendrik; Nydegger, Andreas; Obialo, Nicole; Oneta, Carl; Oropesa, Cassandra; Peter, Ueli; Peternac, Daniel; Petit, Laëtitia Marie; Piccoli–Gfeller, Franziska; Pilz, Julia Beatrice; Raschle, Nadia; Rentsch, Ronald; Restellini, Ronald Sophie; Richterich, Jean-Pierre; Rihs, Sylvia; Ritz, Marc Alain; Roduit, Jocelyn; Rogler, Daniela; Rossel, Jean‐Benoît; Rueger, Vanessa; Saner, Gaby; Sauter, Bernhard; Sawatzki, Mikael; Schäppi, Michela; Scharl, Michael; Scharl, Sylvie; Schelling, Martin; Schibli, Susanne; Schlauri, Hugo; Uebelhart, Sybille Schmid; Schnegg, J. F.; Seibold, Frank; Seirafi, Mariam; Semadeni, Gian-Marco; Semela, David; Senning, Arne; Sidler, Marc; Sokollik, Christiane; Spalinger, Johannes; Spangenberger, Holger; Stadler, Philippe; Steuerwald, Michael; Straumann, Alex; Straumann-Funk, Bigna; Sulz, Michael Christian; Suter, Alexandra; Thorens, Joël; Tiedemann, Sarah; Tutuian, Radu; Vavricka, Stephan R.; Viani, F.; Vögtlin, J; Vonlaufen, Alain; Vouillamoz, D.; Vulliamy, Rachel; Wermuth, Jürg; Werner, Helene; Wiesel, Paul; Wiest, Reiner; Wylie, Tina; Zeitz, Jonas; Zimmermann, Dorothee

doi:10.1093/ije/dyy298

Cited by 29 publications

(34 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, depression and anxiety symptoms were not evaluated by a psychiatric assessment. Even though a broad range of patients was recruited with mild, moderate and severe disease within the SIBDCS, our study was not population‐based and at the beginning of the cohort many patients were recruited from tertiary hospitals 23,24 . However, due to the reasons that multiple hospitals and private practices are enrolling patients to SIBDCS, the possibility of a sample bias should be minimal.…”

Section: Discussionmentioning

confidence: 99%

“…We used prospectively obtained data from the physicians’ and patients’ baseline and annual follow‐up questionnaires from adult patients (≥18 years old) included in the Swiss IBD Cohort study (SIBDCS) 23,24 . SIBDCS is a nation‐wide cohort study enrolling IBD patients in Switzerland since 2006 and is supported by the Swiss National Science Foundation.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Fatigue in inflammatory bowel disease and its impact on daily activities

Schreiner

Rossel

Biedermann

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundFatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life.AimsTo identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life.MethodsWe evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS‐F, range 0‐10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD‐related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS‐F (primary outcome) and FSS scores.ResultsOverall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08‐3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 ‐ 1.123; P < 0.001), younger age at diagnosis (−0.031 per year; −0.042– −0.019; P < 0.001), shorter disease duration (−0.036 per year; −0.050– −0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295‐1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety.ConclusionsFatigue is both more frequent and more severe in patients with IBD than in the general population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Fatigue in inflammatory bowel disease and its impact on daily activities

Schreiner

Rossel

Biedermann

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Data were provided from four different medical centres in Switzerland (Crohn-Colitis-Zentrum Bern and Fribourg, Gastroenterology Inselspital Bern, Gastroenterology Beaulieu Lausanne and Gastroenterology USZ Zu¨rich), and the patients were part of the SIBDCS. 17,18 The data were collected between July 2017 and October 2018. Remission rates and adverse events (AEs) were determined between months 4 and 8 (T1) and between months 12 and 16 (T2) after VDZ induction.…”

Section: Study Design and Patientsmentioning

confidence: 99%

Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements

Mader¹,

Juillerat

Biedermann

et al. 2021

UEG Journal

Self Cite

View full text Add to dashboard Cite

Background Vedolizumab (VDZ), a humanized monoclonal antibody against α4β7-integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid- to long-term efficacy of VDZ using real-life data. Objective Our study aimed to determine the efficacy of VDZ in patients with IBD with and without prior exposure to anti-tumour necrosis factor (TNF) treatments in a real-life setting. Furthermore, we investigated confounding factors influencing the remission to VDZ. Methods Patients participating in the Swiss IBD Cohort Study were included in this study. Remission was defined as calprotectin <200 mg/kg stool and/or mucosal healing determined by endoscopy. End points were determined between months 4 and 8 (T1) and between months 12 and 16 (T2) after VDZ induction. Results Remission was reported in 50.5% (110/218) of patients in T1 (48.7% Crohn’s disease (CD) and 52.5% ulcerative colitis (UC)) and 46.8% (102/218) in T2 (47% CD and 46.5% UC). In UC patients, a significantly higher remission rate was achieved in T2 among anti-TNF-naive patients (57.7%) compared to anti-TNF-experienced patients (34.7%; p = 0.02; odds ratio=0.39, 95% confidence interval 0.17–0.87). In patients with CD, no difference could be seen in either evaluation intervals. Multivariable analysis showed that disease duration significantly influenced remission rates among UC patients. A late response to VDZ therapy with an achievement of remission in T2 was seen in a fifth of all patients (CD 21.7%, UC 20.8%). VDZ treatment was stopped in a third of all patients (31.8%) due to non-response, adverse events or aggravation of extra-intestinal manifestations. Conclusion In a real-life national cohort setting, VDZ induced remission in more than half of IBD patients. Previous treatment with anti-TNF agents was associated with a significant lower efficacy of VDZ in UC but not in CD patients.

show abstract

“…SIBDCS receives ongoing supporting grants from the Swiss National Science Foundation (SNSF) and has been approved by all participating centres' local ethical committees. SIBDCS has been described in detail by Pittet et al [25,26]. Data from all the CD patients enrolled into SIBDCS since its start in 2006, have been used for the analysis in this study.…”

Section: Study Populationmentioning

confidence: 99%

Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study

Frei

Fournier

Zeitz

et al. 2019

Journal of Crohn's and Colitis

Self Cite

View full text Add to dashboard Cite

Background and Aims The optimal timing of treatment escalation in Crohn’s disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS]. Methods Prospectively collected SIBDCS patient data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed in patients with early versus late [<24 versus ≥24 months after diagnosis] and no anti-TNF treatment. Results A reduced risk of developing bowel stenosis was found in patients who received early anti-TNF treatment. This association was seen in patients overall and also in the subgroups of CD patients without pre-existing complications [Log-rank test: p < 0.001]. Furthermore, osteoporosis and anaemia were observed significantly less frequently in patients who received early anti-TNF treatment, compared with either patients who received treatment late [p < 0.001 and p = 0.046, respectively] or were never [p < 0.001 for both] treated with anti-TNF antibodies. Patients with early anti-TNF administration sought medical consultations significantly less often, including gastroenterologists in private practice [p = 0.017], ambulatory [outpatient] hospital visits [p = 0.038], and a composite of any medical visits [p = 0.001]. The percentage of patients unable to work was lowest for early-anti-TNF–treated patients, in comparison with patients who were treated late or never [3.6% vs 8.8% vs 3.7%, p = 0.016]. Conclusions In CD patients within the SIBDCS, early anti-TNF administration was found to be associated with several indicators of a more favourable long-term outcome.

show abstract

Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

Cited by 29 publications

References 55 publications

Fatigue in inflammatory bowel disease and its impact on daily activities

Fatigue in inflammatory bowel disease and its impact on daily activities

Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements

Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study

Contact Info

Product

Resources

About